Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors
22 août 2022 14h00 HE
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Reports Second Quarter 2022 Financial Results and Recent Business Highlights
15 août 2022 16h00 HE
|
Blue Water Vaccines Inc.
Closed private placement in April 2022, with net proceeds of approximately $6.9 millionSigned multiple strategic agreements and collaborations to further vaccine candidate research, development, and...
Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments
10 août 2022 16h00 HE
|
Dyadic International, Inc.
Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from...
Blue Water Vaccines Announces Signing of Sponsored Research Agreement with Cincinnati Children’s Hospital Medical Center for S&P Vaccine Platform Development
20 juil. 2022 14h00 HE
|
Blue Water Vaccines Inc.
CINCINNATI, July 20, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
Global Adult Vaccines Market to Surpass US$ 29,025.87 Million by 2030, Says Coherent Market Insights (CMI)
12 juil. 2022 08h40 HE
|
CMI
Seattle, July 12, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global adult vaccines market is estimated to be valued at US$ 16,790.11 million in 2022 and is expected to...
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
05 juil. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Dyadic to Present at 2022 Jefferies Healthcare Conference
02 juin 2022 09h27 HE
|
Dyadic International, Inc.
JUPITER, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford
31 mai 2022 08h30 HE
|
Blue Water Vaccines Inc.
CINCINNATI, May 31, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate
19 mai 2022 14h00 HE
|
Blue Water Vaccines Inc.
CINCINNATI, May 19, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing vaccines, announces a collaboration...
Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments
13 mai 2022 17h01 HE
|
Blue Water Vaccines Inc.
Closed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate...